B. Riley downgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a neutral rating in a research report report published on Tuesday, December 26th, Marketbeat reports. B. Riley currently has $18.00 target price on the biopharmaceutical company’s stock.
SCMP has been the subject of several other research reports. BidaskClub raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, December 12th. Nomura started coverage on Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a buy rating and a $43.00 target price for the company. Mizuho lowered Sucampo Pharmaceuticals from a buy rating to a neutral rating and decreased their target price for the stock from $14.00 to $12.00 in a research report on Tuesday, October 3rd. UBS Group reduced their price target on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a research report on Thursday, October 12th. Finally, Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 3rd. Six research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $21.58.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $18.05 on Tuesday. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $18.75. The firm has a market cap of $841.80, a price-to-earnings ratio of -5.39, a P/E/G ratio of 5.07 and a beta of 1.45. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.30 EPS. equities analysts expect that Sucampo Pharmaceuticals will post 1.12 EPS for the current year.
In related news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the sale, the insider now owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.13% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Texas Permanent School Fund boosted its position in Sucampo Pharmaceuticals by 2.2% during the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 398 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Sucampo Pharmaceuticals by 36.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 246,796 shares of the biopharmaceutical company’s stock valued at $2,592,000 after purchasing an additional 66,493 shares in the last quarter. Arizona State Retirement System boosted its position in Sucampo Pharmaceuticals by 1.6% during the second quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 200 shares in the last quarter. Rhumbline Advisers boosted its position in Sucampo Pharmaceuticals by 0.9% during the second quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock valued at $513,000 after purchasing an additional 423 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in Sucampo Pharmaceuticals during the second quarter valued at about $199,000. 65.29% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals (SCMP) Downgraded by B. Riley” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://ledgergazette.com/2018/01/13/b-riley-lowers-sucampo-pharmaceuticals-scmp-to-neutral.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.